Inovio Pharmaceuticals (INO)
(Real Time Quote from BATS)
$5.71 USD
-0.23 (-3.79%)
Updated Sep 25, 2024 10:48 AM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Inovio Pharmaceuticals, Inc. [INO]
Reports for Purchase
Showing records 121 - 140 ( 366 total )
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Follow-on Bond Offering Completed; REVEAL 1 Data on Track; BLA Filing in 2022; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Catalyst Rich 2020 - Expecting Phase 3 VGX-3100 - Several Phase 2 Results
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Results Reported; Momentous Data Readouts in 2020; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
INO-5401 Combo Regimen Positive Interim Glioblastoma Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Grant Awarded to Address Antimicrobial Resistance Using dMAb; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 Study in Anal Dysplasia Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Financial Results Reported; Anticipating Multiple Near-Term Data Readouts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive Phase 1 MERS Vaccine Results Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Strategic Focus on Core Clinical Programs; Cash Burn Reduced; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Geneos Therapeutics Spinout Advances Personalized Cancer Vaccine Into First-in-Human Dosing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R